美股市場個股詳情

IMMX Immix Biopharma

添加自選
  • 2.170
  • 0.0000.00%
收盤價 05/01 16:00 (美東)
5729.68萬總市值-2438市盈率TTM
全部分時
  • 5日
  • 日K
  • 周K
  • 月K
  • 季K
  • 年K

資金分布

單位: --

資金流向

實時日周月

暫無數據

新聞

評論

    Jaguar8
    Jaguar8
    04/30 00:28
    $Immix Biopharma(IMMX.US)$
    NEWS
    Immix Biopharma Awarded European Union Orphan Drug Designation for NXC-201 in Multiple Myeloma
    Immix Biopharma, Inc. has been granted European Orphan Drug Designation for NXC-201 in the treatment of multiple myeloma, providing 10 years of market exclusivity, access to centralized authorization procedure, and reduced fees for various applications. The Company aims to address unmet medical needs in frail patients with relapsed/refractory multiple myeloma, with poten...
    Trytosaveabit
    Trytosaveabit
    04/19 04:13

    News

    $Immix Biopharma(IMMX.US)$ Immix Biopharma on Track to Dose First Patients With AL Amyloidosis Therapy by Mid-Year
    MT Newswires· 1 min ago
    Immix Biopharma (IMMX) Thursday said it is on track to dose first patients with relapsed or refractory AL Amyloidosis with its CAR-T NXC-201 therapy candidate by mid-2024 after scheduling initiation visits at US testing locations this month and May.
    The open-label, phase 1b dose-expansion trial is expected to enroll around 40 patients with adequate cardia...
    Jaguar8
    Jaguar8
    04/15 21:37
    $Immix Biopharma(IMMX.US)$
    NEWS
    Immix Biopharma Announces Late-Breaking NXC-201 Clinical Data Abstract Accepted for Oral Presentation at the 27th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT)
    LOS ANGELES, April 15, 2024 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (Nasdaq: IMMX) (“ImmixBio”, “Company”, “We” or “Us” or “IMMX”), a clinical-stage biopharmaceutical company trailblazing cell therapies in AL Amyloidosis and other autoimmune diseases, today announced that updated...
    Trytosaveabit
    Trytosaveabit
    03/20 22:03

    Update

    $Immix Biopharma(IMMX.US)$ Immix Biopharma Announces Major Comprehensive Cancer Center as Lead Site for NXC-201 AL Amyloidosis Clinical Trial
    Trytosaveabit
    Trytosaveabit
    02/09 05:50

    Nice

    $Immix Biopharma(IMMX.US)$ Immix Biopharma Announces Closing of $15 Million Public Offering of Common Stock
    5 MINUTES AGO, 4:45 PM EST
    VIA GLOBENEWSWIRE
閱讀更多

分析

分析師評級

暫無數據

目標價預測

暫無數據

熱議
美股
綜合熱度
股票代碼
最新價
漲跌幅